A Mortalin/HSPA9-Mediated Switch in Tumor-Suppressive Signaling of Raf/MEK/Extracellular Signal-Regulated Kinase

ABSTRACT Dysregulated Raf/MEK/extracellular signal-regulated kinase (ERK) signaling, a common hallmark of tumorigenesis, can trigger innate tumor-suppressive mechanisms, which must be inactivated for carcinogenesis to occur. This innate tumor-suppressive signaling may provide a potential therapeutic target. Here we report that mortalin (HSPA9/GRP75/PBP74) is a novel negative regulator of Raf/MEK/ERK and may provide a target for the reactivation of tumor-suppressive signaling of the pathway in cancer. We found that mortalin is present in the MEK1/MEK2 proteome and is upregulated in human melanoma biopsy specimens. In different MEK/ERK-activated cancer cell lines, mortalin depletion induced cell death and growth arrest, which was accompanied by increased p21CIP1 transcription and MEK/ERK activity. Remarkably, MEK/ERK activity was necessary for mortalin depletion to induce p21CIP1 expression in B-RafV600E-transformed cancer cells regardless of their p53 status. In contrast, in cell types exhibiting normal MEK/ERK status, mortalin overexpression suppressed B-RafV600E- or ΔRaf-1:ER-induced MEK/ERK activation, p21CIP1 expression, and cell cycle arrest. Other HSP70 family chaperones could not effectively replace mortalin for p21CIP1 regulation, suggesting a unique role for mortalin. These findings reveal a novel mechanism underlying p21CIP1 regulation in MEK/ERK-activated cancer and identify mortalin as a molecular switch that mediates the tumor-suppressive versus oncogenic result of dysregulated Raf/MEK/ERK signaling. Our study also demonstrates that p21CIP1 has dual effects under mortalin-depleted conditions, i.e., mediating cell cycle arrest while limiting cell death.

[1]  Michael T. McManus,et al.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference , 2003, Nature Genetics.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  James J. Collins,et al.  Tunable Signal Processing in Synthetic MAP Kinase Cascades , 2011, Cell.

[4]  S. Jones,et al.  Many roads lead to oncogene-induced senescence , 2008, Oncogene.

[5]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[6]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[7]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[8]  S. Kaul,et al.  Functional Significance of Minor Structural and Expression Changes in Stress Chaperone Mortalin , 2007, Annals of the New York Academy of Sciences.

[9]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[10]  Jong-In Park,et al.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. , 2011, Experimental cell research.

[11]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[12]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[13]  Kazunari Taira,et al.  Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. , 2003, Biochemical and biophysical research communications.

[14]  S. Turner,et al.  Jailbreak: oncogene-induced senescence and its evasion. , 2011, Cellular signalling.

[15]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[16]  F. Beier,et al.  The Raf-1/MEK/ERK Pathway Regulates the Expression of the p21Cip1/Waf1 Gene in Chondrocytes* , 1999, The Journal of Biological Chemistry.

[17]  J. Luk,et al.  Mortalin–p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy , 2011, Cell Death and Differentiation.

[18]  P. Cuatrecasas,et al.  Mitogen-activated Protein Kinase Kinase Inhibition Does Not Block the Stimulation of Glucose Utilization by Insulin (*) , 1995, The Journal of Biological Chemistry.

[19]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[20]  G. Gillet,et al.  Non-apoptotic roles of Bcl-2 family: the calcium connection. , 2013, Biochimica et biophysica acta.

[21]  A. Skoultchi,et al.  GATA-1 directly regulates p21 gene expression during erythroid differentiation , 2010, Cell cycle.

[22]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[23]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[24]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[25]  J. Espinosa,et al.  The p53 circuit board. , 2012, Biochimica et biophysica acta.

[26]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[27]  M. Jäättelä,et al.  The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions , 2007, FEBS letters.

[28]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[29]  M. Sherman,et al.  HSP72 depletion suppresses γH2AX activation by genotoxic stresses via p53/p21 signaling , 2010, Oncogene.

[30]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[31]  Bernd Bukau,et al.  The Hsp70 and Hsp60 Chaperone Machines , 1998, Cell.

[32]  D. Peeper,et al.  Oncogene-induced cell senescence--halting on the road to cancer. , 2006, The New England journal of medicine.

[33]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[34]  F. Besançon,et al.  Inactivation of p21 WAF1 Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio* , 2002, The Journal of Biological Chemistry.

[35]  H. Kampinga,et al.  The HSP70 chaperone machinery: J proteins as drivers of functional specificity , 2010, Nature Reviews Molecular Cell Biology.

[36]  M. O’Reilly,et al.  Cell Injury , Repair , Aging and Apoptosis p 21 Cip 1 Protection against Hyperoxia Requires Bcl-XL and Is Uncoupled from Its Ability to Suppress Growth , 2010 .

[37]  S. Kaul,et al.  Reduction in mortalin level by its antisense expression causes senescence‐like growth arrest in human immortalized cells , 2004, The journal of gene medicine.

[38]  R. Reddel,et al.  Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis , 2006, International journal of cancer.

[39]  M. O’Reilly,et al.  p21Cip1/Waf1/Sdi1 protects against hyperoxia by maintaining expression of Bcl-XL , 2006 .

[40]  G. Robertson,et al.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. , 2008, Cancer research.

[41]  Jong-In Park,et al.  Noncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling* , 2009, The Journal of Biological Chemistry.

[42]  F. Alt,et al.  Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer , 2006, Proceedings of the National Academy of Sciences.

[43]  M. Sherman,et al.  Hsp27 modulates p53 signaling and suppresses cellular senescence. , 2007, Cancer research.

[44]  K. Flaherty,et al.  p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. , 2012, The Journal of investigative dermatology.

[45]  Rony Seger,et al.  The MEK/ERK cascade: from signaling specificity to diverse functions. , 2007, Biochimica et biophysica acta.

[46]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[47]  Chang Gun Kim,et al.  The ETS Family Transcription Factor ELK-1 Regulates Induction of the Cell Cycle-regulatory Gene p21Waf1/Cip1 and the BAX Gene in Sodium Arsenite-exposed Human Keratinocyte HaCaT Cells* , 2011, The Journal of Biological Chemistry.

[48]  J. Yates,et al.  PRAK Is Essential for ras-Induced Senescence and Tumor Suppression , 2007, Cell.

[49]  J. Selkirk,et al.  Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts. , 1997, Cancer letters.

[50]  A. Helwak,et al.  Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions , 2009, Oncogene.

[51]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[52]  S. Kaul,et al.  Three faces of mortalin: A housekeeper, guardian and killer , 2007, Experimental Gerontology.

[53]  T. Hirano,et al.  Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. , 2005, The Biochemical journal.

[54]  S. Deraz,et al.  Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? , 2011, Biochimica et biophysica acta.

[55]  G. M. Wilson,et al.  Sulforaphane Induction of p21Cip1 Cyclin-dependent Kinase Inhibitor Expression Requires p53 and Sp1 Transcription Factors and Is p53-dependent* , 2012, The Journal of Biological Chemistry.

[56]  J. Boros,et al.  Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein* , 2004, Journal of Biological Chemistry.

[57]  R. Reddel,et al.  Inactivation of Tumor Suppressor p53 by Mot-2, a hsp70 Family Member* , 1998, The Journal of Biological Chemistry.

[58]  M. McMahon,et al.  Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase , 1993, Molecular and cellular biology.